

DAFTAR PUSTAKA

1. Ferreiro L, San José ME, Valdés L. Management of Parapneumonic Pleural Effusion in Adults. *Arch Bronconeumol* 2015; 51: 637–646. DOI: 10.1016/j.arbr.2015.10.002.
2. Yousaf Z, Ata F, Chaudhary H, et al. Etiology, pathological characteristics, and clinical management of black pleural effusion: A systematic review. *Med (United States)*; 101. DOI: 10.1097/MD.00000000000028130.
3. Lin L, Li S, Xiong Q, et al. A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion. *BMC Pulm Med* 2021; 21: 1–10. DOI: 10.1186/s12890-021-01459-w.
4. Kemenkes RI. Hasil Utama Riset Kesehatan Dasar Tahun 2018. *Kementrian Kesehat Republik Indones* 2018; 1–100.
5. Habas EM, Habas A, Said A, et al. Diagnostic approach to pleural effusion based on pathogenesis and radiological findings: A narrative review. *Yemen J Med* 2024; 3: 102–113. DOI: 10.18231/j.yjom.2024.006.
6. Hallifax RJ, Talwar A, Wrightson JM, et al. State-of-the-art: Radiological investigation of pleural disease. *Respir Med* 2017; 124: 88–99. DOI: 10.1016/j.rmed.2017.02.013.
7. Zaki HA, Albaroudi B, Shaban EE, et al. Advancement in pleura effusion diagnosis: a systematic review and meta-analysis of point-of-care ultrasound versus radiographic thoracic imaging. *Ultrasound J*; 16. DOI: 10.1186/s13089-023-00356-z.
8. Cao X-S, Zheng W-Q, Zhi-De Hu. Diagnostic value of soluble biomarkers for parapneumonic pleural effusion. *Crit Rev Clin Lab Sci* 2023; 60: 233–247.
9. Sadullahoğlu C. The role of cytology in pleural effusion: a single-center experience. *Erciyes Med J*. DOI: 10.14744/etd.2019.88557.
10. Wu H, Khosla R, Rohatgi PK, et al. The minimum volume of pleural fluid required to diagnose malignant pleural effusion: A retrospective study. *Lung*

India 2017; 34: 34–37. DOI: 10.4103/0970-2113.197120.

11. Li C, Kazzaz FI, Scoon JM, et al. Lymphocyte predominant exudative pleural effusions: A narrative review. *Shanghai Chest* 2022; 6: 1–11. DOI: 10.21037/shc-21-11.
12. Zhou G, Liu K, Ji X, et al. Diagnosis of parapneumonic pleural effusion with serum and pleural fluid Activin A. *Clinics* 2022; 77: 100133. DOI: 10.1016/j.clinsp.2022.100133.
13. Blakiston M, Chiu W, Wong C, et al. Diagnostic performance of pleural fluid adenosine deaminase for tuberculous pleural effusion in a low-incidence setting. *J Clin Microbiol* 2018; 56: 1–8. DOI: 10.1128/JCM.00258-18.
14. Jiménez Castro D, Díaz Nuevo G, Pérez-Rodríguez E, et al. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. *Eur Respir J* 2003; 21: 220–224. DOI: 10.1183/09031936.03.00051603.
15. Pande K, Shrestha S, Shrestha A, et al. Role of pleural fluid adenosine deaminase activity and lymphocytosis in the etiological diagnosis. *J Pathol Nepal* 2016; 6: 1008–1012. DOI: 10.3126/jpn.v6i12.16290.
16. Mercer RM, Corcoran JP, Porcel JM, et al. Interpreting pleural fluid results. *Clin Med J R Coll Physicians London* 2019; 19: 213–217. DOI: 10.7861/clinmedicine.19-3-213.
17. Sandeesha V, Kiran CVR, Ushakiran P, et al. A comparative study of serum effusion albumin gradient and Light's criteria to differentiate exudative and transudative pleural effusion. *J Fam Med Prim Care* 2020; 9: 4847–52. DOI: 10.4103/jfmprc.jfmprc.
18. Sharma K, Fultariya L, Reddy Mallimala P, et al. Comparison of the Efficacy of Light's Criteria With Serum-Effusion Albumin Gradient and Pleural Effusion Glucose. *Cureus*; 15. DOI: 10.7759/cureus.43319.
19. Mohan G, Bhide P, Agrawal A, et al. A practical approach to pseudoexudative pleural effusions. *Respir Med* 2023; 214: 107279. DOI: 10.1016/j.rmed.2023.107279.
20. Krishna R, Antoine MH, Alahmadi MH, et al. Pleural Effusion. *StatPearls [Internet] Treasure Isl StatPearls Publ.*

21. Li D, Ajmal S, Tufail M, et al. Modern day management of a unilateral pleural effusion. *Clin Med J R Coll Physicians London* 2021; 21: E561–E566. DOI: 10.7861/clinmed.2021-0617.
22. Elkins MR. Physiotherapy management of pleural effusion. *J Physiother* 2025; 71: 152–157. DOI: 10.1016/j.jphys.2025.06.009.
23. Singh S, Singh SK, Tentu AK. Management of parapneumonic effusion and empyema. *J Assoc Chest Physicians* 2019; 7: 51–58. DOI: 10.1136/ad.88.10.915.
24. Shebl E, Paul M. Parapneumonic Pleural Effusions and Empyema Thoracis. *StatPearls [Internet] Treasure Isl StatPearls Publ.*
25. Karkhanis VS, Joshi JM. Pleural effusion: Diagnosis, treatment, and management. *Open Access Emerg Med* 2012; 4: 31–52. DOI: 10.2147/OAEM.S29942.
26. Kalantri S, Joshi R, Lokhande T, et al. Accuracy and reliability of physical signs in the diagnosis of pleural effusion. *Respir Med* 2007; 101: 431–438. DOI: 10.1016/j.rmed.2006.07.014.
27. Nicholson MJ, Manley C, Ahmad D. Thoracentesis for the Diagnosis and Management of Pleural Effusions: The Current State of a Centuries-Old Procedure. *J Respir* 2023; 3: 208–222. DOI: 10.3390/jor3040020.
28. Yavuz MY, Dogan BI, Anar C, et al. Diagnostic Value of Pleural Fluid Biochemical Parameters and Ratios for Differentiating Tuberculous Pleurisy from Parapneumonic Effusion and Malignant Effusion. *J İzmir Chest Hosp* 2023; 37: 34–40. DOI: 10.14744/igh.2023.85520.
29. Singh J, Singh K, Saini R, et al. Diagnostic role of different biochemical parameters in pleural effusion. *Int J Clin Biochem Res* 2022; 9: 291–294. DOI: 10.18231/j.ijcbr.2022.057.
30. Singh S, Singh SK, Tentu AK. Management of Parapneumonic Effusion and Empyema. *J Assoc Chest Physicians* 2019; 7: 241–249. DOI: 10.1016/j.ccm.2025.02.003.
31. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college

- of chest physicians evidence-based clinical practice guidelines. *Chest* 2013; 143: e142S-e165S. DOI: 10.1378/chest.12-2353.
32. Docks B. Pathophysiology, etiology, treatment/management of pleural effusion under disease conditions. *J Clin Resp Med* 2022; 6: 110. DOI: 10.35841/aajcrm-6.2.110.
 33. Karpathiou G, Peoc'h M. Pleura revisited: From histology and pathophysiology to pathology and molecular biology. *Clin Respir J* 2019; 13: 3–13. DOI: 10.1111/crj.12982.
 34. Miserocchi G. Mechanisms controlling the volume of pleural fluid and extravascular lung water. *Eur Respir Rev* 2009; 18: 244–252. DOI: 10.1183/09059180.00002709.
 35. Psallidas I, Kalomenidis I, Porcel JM, et al. Malignant pleural effusion: From bench to bedside. *Eur Respir Rev* 2016; 25: 189–198. DOI: 10.1183/16000617.0019-2016.
 36. Jovanovic D. Etiopathogenesis of malignant pleural effusion. *AME Med J* 2021; 6: 1–7. DOI: 10.21037/amj-2019-mpe-05.
 37. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. *Jama* 2012; 307: 2383–2389. DOI: 10.1001/jama.2012.5535.
 38. Bazerbashi S, Villaquiran J, Awan MY, et al. Ambulatory intercostal drainage for the management of malignant pleural effusion: A single center experience. *Ann Surg Oncol* 2009; 16: 3482–3487. DOI: 10.1245/s10434-009-0691-2.
 39. Yalcin NG, Choong CKC, Eizenberg N. Anatomy and Pathophysiology of the Pleura and Pleural Space. *Thorac Surg Clin* 2013; 23: 1–10. DOI: 10.1016/j.thorsurg.2012.10.008.
 40. Demmy TL, Gu L, Burkhalter JE, et al. Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102). *J Natl Compr Canc Netw* 2012; 10: 975–982.
 41. Giannou AD, Agalioi T, Georgios T, et al. Mast cells mediate malignant

- pleural effusion formation Find the latest version: Mast cells mediate malignant pleural effusion formation. *J Clin Invest* 2015; 125: 2317–2334. DOI: 10.1172/JCI79840.In.
42. Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of Malignant pleural effusion in patients with non-small cell lung cancer (review). *Mol Med Rep* 2018; 17: 8019–8030. DOI: 10.3892/mmr.2018.8922.
 43. Cui R, Takahashi F, Ohashi R, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. *Lung Cancer* 2009; 63: 368–374. DOI: 10.1016/j.lungcan.2008.06.020.
 44. Stathopoulos GT, Kalomenidis I. Malignant pleural effusion : tumor-host interactions unleashed. *Am J Respir Crit Care Med* 201M; 186: 487–492. DOI: 10.1164/rccm.201203-0465PP.Malignant.
 45. Porcel JM, Bielsa S, Esquerda A, et al. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. *Eur J Intern Med* 2012; 23: 447–450. DOI: 10.1016/j.ejim.2012.03.002.
 46. Drăgoescu AN, Pădureanu V, Stănculescu AD, et al. Neutrophil to Lymphocyte Ratio (NLR)—A Useful Tool for the Prognosis of Sepsis in the ICU. *Biomedicines*; 10.
 47. Parmelia M, Sutarka IN. Neutrophil-Lymphocyte Ratio as Predictor of Mortality in Regular Hemodialysis Patients at Tabanan General Hospital. *Unram Med J* 2023; 12: 150–156. DOI: 10.29303/jk.v12i2.4389.
 48. Thayalan D, Anandan N, Rajkumar K, et al. Prognostic significance of neutrophil to lymphocyte ratio (NLR) in oral squamous cell carcinoma. *Oral Oncol Reports* 2024; 11: 100604. DOI: 10.1016/j.oor.2024.100604.
 49. Popowicz N, Cheah HM, Gregory C, et al. Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. *PLoS One* 2021; 16: 1–12. DOI: 10.1371/journal.pone.0250628.
 50. Ewida E, Abd Elnaby HE, Deraz E, et al. Diagnostic Value of Neutrophil-Lymphocyte Ratio in Exudative Pleural Effusion. *Al-Azhar Int Med J* 2022;

- 0: 0–0. DOI: 10.21608/aimj.2022.137606.1940.
51. Guerra SS, Ferro R, Abrantes T, et al. Pleural fluid lactate: a diagnostic tool in pleural effusion management? *J Bras Pneumol* 2022; 48: 6–8. DOI: 10.36416/1806-3756/e20220350.
 52. He T, Oh S. Diagnostic approach to pleural effusion. *AME Med J* 2018; 90: 116. DOI: 10.21037/amj.2018.12.02.
 53. Villena Garrido V, Cases Viedma E, Fernández Villar A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. *Arch Bronconeumol* 2014; 50: 235–249. DOI: 10.1016/j.arbr.2014.04.007.
 54. Aleksiev V, Markov D, Yavorov B, et al. Enhanced diagnostic approaches for malignant pleural effusions: An extensive biochemical and statistical analysis. *Folia Med (Plovdiv)* 2025; 67: 1–11. DOI: 10.3897/folmed.67.e145825.
 55. Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. *Front Immunol* 2018; 9: 1–11. DOI: 10.3389/fimmu.2018.00754.
 56. Zhou HH, Tang YL, Xu TH, et al. C-reactive protein: structure, function, regulation, and role in clinical diseases. *Front Immunol* 2024; 15: 1–11. DOI: 10.3389/fimmu.2024.1425168.
 57. Mitsis A, Sokratous S, Karmioti G, et al. The Role of C-Reactive Protein in Acute Myocardial Infarction: Unmasking Diagnostic, Prognostic, and Therapeutic Insights. *J Clin Med* 2025; 14: 1–18. DOI: 10.3390/jcm14134795.
 58. Falguera M, Carratalà J, Bielsa S, et al. Predictive factors, microbiology and outcome of patients with parapneumonic effusion. *Eur Respir J* 2011; 38: 1173–1179. DOI: 10.1183/09031936.00000211.
 59. Odeh M, Kogan Y, Sabo E. Diagnostic Efficacy of C-Reactive Protein in Differentiating Various Causes of Exudative Pleural Effusion: Disease Research Should Not Be Exclusive to the Wealthy †. *Adv Respir Med* 2025; 93: 1–17. DOI: 10.3390/arm93040029.
 60. Roy B, Shak HJ, Lee YCG. Pleural fluid investigations for pleural infections.

J Lab Precis Med 2021; 6: 1–13. DOI: 10.21037/jlpm-2021-01.

61. Ferreiro L, Lado-Baleato Ó, Suárez-Antelo J, et al. Diagnosis of infectious pleural effusion using predictive models based on pleural fluid biomarkers. *Ann Thorac Meedicine* 2019; 14: 254–263. DOI: 10.4103/atm.ATM.
62. Aggarwal AN, Agarwal R, Dhooria S, et al. Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. *PLoS One* 2019; 14: 1–11. DOI: 10.1016/j.cyto.2022.156019.
63. Shimoda M, Hirata A, Tanaka Y, et al. Characteristics of pleural effusion with a high adenosine deaminase level: a case–control study. *BMC Pulm Med* 2022; 22: 1–10. DOI: 10.1186/s12890-022-02150-4.
64. Mittal N, Das B. Role of Adenosine Deaminase (ADA) in Etiological Classification of Exudative Pleural Effusion. *Int J Res Rev* 2020; 7: 1.
65. Lee J, Yoo SS, Lee SY, et al. Pleural fluid adenosine deaminase/serum C-reactive protein ratio for the differentiation of tuberculous and parapneumonic effusions with neutrophilic predominance and high adenosine deaminase levels. *Infection* 2017; 45: 59–65. DOI: 10.1007/s15010-016-0928-5.
66. Kaewwinud J, Pienchitlertkajorn S, Koomtanapat K, et al. Diagnostic scoring systems for tuberculous pleural effusion in patients with lymphocyte-predominant exudative pleural profile: A development study. *Heliyon* 2024; 10: e23440. DOI: 10.1016/j.heliyon.2023.e23440.
67. Park HJ, Choi CM. Can parapneumonic effusion be diagnosed only with pleural fluid analysis? *J Thorac Dis* 2020; 12: 3422–3425. DOI: 10.21037/jtd.2020.02.02.
68. Tarigan LY, Iskandar D. Pemeriksaan Adenosine Deaminase (ADA) sebagai Alternatif Diagnosis TB pada Anak. *Cermin Dunia Kedokt* 2022; 49: 382–385. DOI: 10.55175/cdk.v49i7.253.
69. Da Silva CT, Behrsin RF, Cardoso GP, et al. Evaluation of adenosine deaminase activity for the diagnosis of pleural TB in lymphocytic pleural effusions. *Biomark Med* 2013; 7: 113–118. DOI: 10.2217/bmm.12.89.
70. Gao ZW, Yang L, Liu C, et al. Distinct Roles of Adenosine Deaminase

- Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis. *Front Immunol* 2022; 13: 1–12. DOI: 10.3389/fimmu.2022.903461.
71. Sapkota LB, Thapa S, Subedi N. Correlation study of adenosine deaminase and its isoenzymes in type 2 diabetes mellitus. *BMJ Open Diabetes Res Care* 2017; 5: 1–6. DOI: 10.1136/bmjdr-2016-000357.
 72. Martinez-Navio JM, Casanova V, Pacheco R, et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4⁺ T cells. *J Leukoc Biol* 2010; 89: 127–136. DOI: 10.1189/jlb.1009696.
 73. Lee SJ, Kim HS, Lee SH, et al. Factors influencing pleural adenosine deaminase level in patients with tuberculous pleurisy. *Am J Med Sci* 2014; 348: 362–365. DOI: 10.1097/MAJ.0000000000000260.
 74. Goyal A, Kaur A, Kajal NC. Diagnostic value of pleural fluid adenosine deaminase level in patients of tubercular pleural effusion. *Int J Adv Med* 2020; 8: 93. DOI: 10.18203/2349-3933.ijam20205479.
 75. Wand O, Fox BD, Shtraichman O, et al. Non-tuberculous, adenosine deaminase-positive lymphocytic pleural effusion: Consider immunoglobulin G4-related disease. *Sarcoidosis Vasc Diffus Lung Dis* 2020; 37: 225–230. DOI: 10.36141/svdld.v37i2.9098.
 76. Barreto DB, Rodriguez EP, Gotera C, et al. Lymphocytic Pleural Effusion and Change of the Adenosine Deaminase Cut-Off Level in Tuberculosis Diagnosis. *Chest* 2014; 145: 274A. DOI: 10.1378/chest.1821853.
 77. Choe J, Shin SH, Jeon K, et al. Features which discriminate between tuberculosis and haematologic malignancy as the cause of pleural effusions with high adenosine deaminase. *Respir Res* 2024; 25: 1–9. DOI: 10.1186/s12931-023-02645-6.
 78. Negida A, Fahim NK, Negida Y. Sample Size Calculation Guide - Part 4: How to Calculate the Sample Size for a Diagnostic Test Accuracy Study based on Sensitivity, Specificity, and the Area Under the ROC Curve. *Adv J Emerg Med* 2019; 3: e33. DOI: 10.22114/ajem.v0i0.158.
 79. Mortazavi-Moghaddam SGR, Sharifzadeh GR, Rezvani MR. Pleural Fluid Adenosine Deaminase Values in Diagnosis of Tuberculous Pleural Effusion

- in South Khorasan Province. *Zahedan J Res Med Sci*; In Press. DOI: 10.17795/zjrms-5219.
80. Hakani L, Mitre A. A clinical study of diagnostic efficacy of interferon gamma and adenosine deaminase in exudative pleural effusion. *Int J Adv Med* 2016; 3: 148–151. DOI: 10.18203/2349-3933.ijam20160835.
 81. Hussein M, Thomas M, Al-Tikrity M, et al. Etiology of exudative pleural effusion among adults: differentiating between tuberculous and other causes, a multicenter prospective cohort study. *IJID Reg* 2024; 12: 100425. DOI: 10.1016/j.ijregi.2024.100425.
 82. Lei X, Wang J, Yang Z, et al. Diagnostic Value of Pleural Effusion Mononuclear Cells Count and Adenosine Deaminase for Tuberculous Pleurisy Patients in China: A Case-Control Study. *Front Med*; 6. DOI: 10.3389/fmed.2019.00301.
 83. Vasudha KC, Nirmal Kumar A, Venkatesh T. Studies on the age dependent changes in serum adenosine deaminase activity and its changes in hepatitis. *Indian J Clin Biochem* 2006; 21: 116–120. DOI: 10.1007/BF02913078.
 84. Weyand CM, Goronzy JJ. Aging of the immune system: Mechanisms and therapeutic targets. *Ann Am Thorac Soc* 2016; 13: S422–S428. DOI: 10.1513/AnnalsATS.201602-095AW.
 85. Maranhão BHF, Da Silva Junior CT, Barillo JL, et al. Diagnostic Accuracy with Total Adenosine Deaminase as a Biomarker for Discriminating Pleural Transudates and Exudates in a Population-Based Cohort Study. *Dis Markers* 2021; 2021: 1–7. DOI: 10.1155/2021/6648535.
 86. Lokman YB, Putra DD, Tarigan SP, et al. Thoracic CT Scan Image in Transudate and Exudate Pleural Effusion Cases at Haji Adam Malik General Hospital Medan in January - September 2024. *J Soc Med* 2024; 3: 389–396. DOI: 10.71197/jsocmed.v3i12.185.
 87. Saminathan P, Mathews IT, Alimadadi A, et al. Sex differences in adenosine deaminase activity associate with disparities in SARS-CoV-2 innate immunity. *iScience* 2025; 28: 112418. DOI: 10.1016/j.isci.2025.112418.
 88. Tavalani H, Sheikh N, Vaisi-raygani A, et al. Sex differences in adenosine

- deaminase activity of stroke patients. *Clin Chem Lab Med* 2008; 46: 506–509.
89. Nordjannah N, Kartini A, ER D. Evaluation of Pleural Effusion Type Determination Based on Light's and Heffner's Criteria. *Indones J Clin Pathol Med Lab* 2023; 26: 76–80. DOI: 10.24293/ijcpml.v26i1.2181.
 90. Auliya H, Roza Kurniati, Fauzar. Diagnosis and Management of Malignant Pleural Effusion: A Narrative Literature Review. *Biosci Med J Biomed Transl Res* 2022; 6: 2449–2456. DOI: 10.37275/bsm.v6i12.624.
 91. Syahrudin E, Hudoyo A, Arief N. Efusi pleura ganas pada kanker paru. *J Respir Indo* 2020; 29: 1–9, <http://arsip.jurnalrespirologi.org/efusi-pleura-ganas-pada-kanker-paru/> (2020).
 92. Uzbek MH, Almeida FA, Sarkiss MG, et al. Management of malignant pleural effusions. *Adv Ther* 2010; 27: 334–347. DOI: 10.1007/S12325-010-0031-8.
 93. Bediwy AS, Al-Biltagi M, Saeed NK, et al. Pleural effusion in critically ill patients and intensive care setting. *World J Clin Cases* 2023; 11: 989–999. DOI: 10.12998/wjcc.v11.i5.989.
 94. Zhang X, Meng Q, Miao R, et al. The diagnostic value of T cell spot test and adenosine deaminase in pleural effusion for tuberculous pleurisy: A systematic review and meta-analysis. *Tuberculosis* 2022; 135: 102223. DOI: 10.1016/j.tube.2022.102223.
 95. Dewi PPAP, Aryati A, Anniwati L, et al. Correlation Between Adenosine Deaminase Activity in Pleural Fluid and Serum of Patients With Pleural Effusion. *Indones J Clin Pathol Med Lab* 2018; 24: 180–184. DOI: 10.24293/ijcpml.v24i2.1321.
 96. Nakajima Y, Kuribayashi K, Ishigaki H, et al. Adenosine Deaminase in Pleural Effusion and Its Relationship with Clinical Parameters in Patients with Malignant Pleural Mesothelioma. *Cancer Invest* 2020; 38: 356–364. DOI: 10.1080/07357907.2020.1776313.
 97. Li R, Wang J, Wang X, et al. Pleural effusion adenosine deaminase: A candidate biomarker to discriminate between Gram-negative and Gram-

- positive bacterial infections of the pleural space. *Clinics* 2016; 71: 271–275. DOI: 10.6061/clinics/2016(05)05.
98. Kouritas VK, Hatzoglou C, Foroulis CN, et al. Low glucose level and low pH alter the electrochemical function of human parietal pleura. *Eur Respir J* 2007; 30: 354–357. DOI: 10.1183/09031936.00047106.
 99. Michaela C, Putra NPP, Djajalaksana S, et al. Significance Level of Pleural Fluid Tissue Inhibitor Metalloproteinase-1 (TIMP-1) and Glucose Levels as Biomarkers of Malignant Pleural Effusion. *J Respirasi* 2025; 11: 208–215. DOI: 10.20473/jr.v11-i.3.2025.208-215.
 100. Fitzgerald DB, Leong SL, Budgeon CA, et al. Relationship of pleural fluid pH and glucose: A multi-centre study of 2,971 cases. *J Thorac Dis* 2019; 11: 123–130. DOI: 10.21037/jtd.2018.12.101.
 101. Addala DN, Denniston P, Sundaralingam A, et al. Optimal diagnostic strategies for pleural diseases and identifying high-risk patients. *Expert Rev Respir Med* 2023; 17: 15–26. DOI: 10.1080/17476348.2023.2174527.
 102. Novianti DA, Wardhani P. Massive Pleural Effusion with Adenosine Deaminase (ADA) Test Positive and COVID-19 Confirmed: A Case Report. *Pharmacogn J* 2022; 14: 450–454. DOI: 10.5530/pj.2022.14.120.
 103. Gupta B. Role of Adenosine Deaminase Estimation in Differentiation of Tuberculous and Non-tuberculous Exudative Pleural Effusions. *J Clin Med Res* 2010; 2: 79–84. DOI: 10.4021/jocmr2010.03.280w.